Company
Eisai
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
15
11 still marketed
Novel approvals
9
Approvals since 2021
15
Originals and new uses
Phase 3 trials
101
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Lenvima new use OrphanSep 24, 2026
- Leqembi Iqlik new use Priority reviewJul 13, 2026
- Leqembi Iqlik approved Aug 29, 2025
- Lenvima new use Priority reviewOrphanJan 29, 2025
- Leqembi new use Jan 24, 2025
- Lenvima new use OrphanJun 7, 2024
- Lenvima new use Priority reviewOrphanApr 3, 2024
- Lenvima new use OrphanOct 23, 2023
- Leqembi new use Priority reviewJul 6, 2023
- Dayvigo new use Apr 20, 2023
Drugs in development (8)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- BB-1701Phase 21 trial
Eisai · Breast Cancer
- E2086Phase 21 trial
Eisai · Narcolepsy
- E2814Phase 21 trial
Eisai · Alzheimer's Disease
- E6742Phase 21 trial
Eisai · Systemic Lupus Erythematosus
- E7090Phase 21 trial
Eisai · Cholangiocarcinoma
- E7386Phase 21 trial
Eisai · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular
- E7389-LFPhase 21 trial
Eisai · Solid Neoplasms
- Farletuzumab ecteribulinMORAb-202Phase 21 trial
Eisai · Solid Tumor
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (11)
Newest FDA action first.
- Lenvima Lenvatinib Mesylate · 2015
- Leqembi Iqlik Lecanemab-Irmb · 2025
- Leqembi Lecanemab-Irmb · 2023
- Dayvigo Lemborexant · 2019
- Banzel Rufinamide · 2011
- Halaven Eribulin Mesylate · 2010
- Ontak Denileukin Diftitox · 1999
- Banzel Rufinamide · 2008
- Aricept Donepezil Hydrochloride · 2010
- Aricept Donepezil Hydrochloride · 1996
- Aciphex Rabeprazole Sodium · 2002
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.